Atea Pharmaceuticals shares are trading lower. The company announced topline findings from its pivotal North American Phase 3 C-BEYOND clinical trial evaluating its oral antiviral therapy for chronic hepatitis C virus infection.

Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7

Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.

Atea Pharmaceuticals Q2 EPS $(0.41) Beats $(0.56) Estimate

Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.